The approval of BTK and PI3K inhibitors (ibrutinib, idelalisib) represents a revolution in the therapy of B cell malignancies such as chronic lymphocytic leukemia (CLL), mantle-cell lymphoma (MCL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), or Waldenström's macroglobulinemia (WM). However, these "BCR inhibitors" function by interfering with B cell pathophysiology in a more complex way than anticipated, and resistance develops through multiple mechanisms. In ibrutinib treated patients, the most commonly described resistance-mechanism is a mutation in BTK itself, which prevents the covalent binding of ibrutinib, or a mutation in PLCG2, which acts to bypass the dependency on BTK at the BCR signalosome. However, additional genetic aberrations leading to resistance are being described (such as mutations in the CARD11, CCND1, BIRC3, TRAF2, TRAF3, TNFAIP3, loss of chromosomal region 6q or 8p, a gain of Toll-like receptor (TLR)/MYD88 signaling or gain of 2p chromosomal region). Furthermore, relative resistance to BTK inhibitors can be caused by non-genetic adaptive mechanisms leading to compensatory pro-survival pathway activation. For instance, PI3K/mTOR/Akt, NFkB and MAPK activation, BCL2, MYC, and XPO1 upregulation or PTEN downregulation lead to B cell survival despite BTK inhibition. Resistance could also arise from activating microenvironmental pathways such as chemokine or integrin signaling via CXCR4 or VLA4 upregulation, respectively. Defining these compensatory pro-survival mechanisms can help to develop novel therapeutic combinations of BTK inhibitors with other inhibitors (such as BH3-mimetic venetoclax, XPO1 inhibitor selinexor, mTOR, or MEK inhibitors). The mechanisms of resistance to PI3K inhibitors remain relatively unclear, but some studies point to MAPK signaling upregulation via both genetic and non-genetic changes, which could be co-targeted therapeutically. Alternatively, drugs mimicking the BTK/PI3K inhibition effect can be used to prevent adhesion and/or malignant B cell migration (chemokine and integrin inhibitors) or to block the pro-proliferative T cell signals in the microenvironment (such as IL4/STAT signaling inhibitors). Here we review the genetic and non-genetic mechanisms of resistance and adaptation to the first generation of BTK and PI3K inhibitors (ibrutinib and idelalisib, respectively), and discuss possible combinatorial therapeutic strategies to overcome resistance or to increase clinical efficacy.

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czechia

Molecular Medicine CEITEC Masaryk University Brno Czechia

Zobrazit více v PubMed

Devan J, Janikova A, Mraz M. New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs. Semin Oncol (2018) 45:291–302.  10.1053/j.seminoncol.2018.07.005 PubMed DOI

Dühren-von Minden M, Übelhart R, Schneider D, Wossning T, Bach MP, Buchner M, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature (2012) 489:309–12.  10.1038/nature11309 PubMed DOI

Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C, et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood (2002) 100:3741–8.  10.1182/blood-2002-02-0539 PubMed DOI

Saba NS, Liu D, Herman SEM, Underbayev C, Tian X, Behrend D, et al. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. Blood (2016) 128:82–92.  10.1182/blood-2015-11-681460 PubMed DOI PMC

Seda V. Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol (2015) 94:193–205.  10.1111/ejh.12427 PubMed DOI

Lew TE, Anderson MA, Seymour JF. Promises and pitfalls of targeted agents in chronic lymphocytic leukemia. Cancer Drug Resist (2020) 3:415–44.  10.20517/cdr.2019.108 PubMed DOI PMC

Woyach JA, Furman RR, Liu T-M, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med (2014) 370:2286–94.  10.1056/NEJMoa1400029 PubMed DOI PMC

Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood (2014) 123:3390–7.  10.1182/blood-2013-11-535047 PubMed DOI PMC

Wilson WH, Gerecitano JF, Goy A, de Vos S, Kenkre VP, Barr PM, et al. The Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study. Blood (2012) 120:686–6.  10.1182/blood.V120.21.686.686 DOI

Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol (2018) 183:578–87.  10.1111/bjh.15567 PubMed DOI

Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica (2018) 103:874–9.  10.3324/haematol.2017.182907 PubMed DOI PMC

Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood (2018) 131:182–90.  10.1182/blood-2017-09-804641 PubMed DOI PMC

Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia. New Engl J Med (2015) 372:1430–40.  10.1056/NEJMoa1501548 PubMed DOI

Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica (2017) 102:e156–9.  10.3324/haematol.2016.151738 PubMed DOI PMC

Rolli V, Gallwitz M, Wossning T, Flemming A, Schamel WWA, Zürn C, et al. Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop. Mol Cell (2002) 10:1057–69. 10.1016/S1097-2765(02)00739-6 PubMed DOI

Aiba Y, Kameyama M, Yamazaki T, Tedder TF, Kurosaki T. Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase. Blood (2008) 111:1497–503.  10.1182/blood-2007-08-109769 PubMed DOI

Okada T, Maeda A, Iwamatsu A, Gotoh K, Kurosaki T. BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. Immunity (2000) 13:817–27. 10.1016/S1074-7613(00)00079-0 PubMed DOI

Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 307:1098–101.  10.1126/science.1106148 PubMed DOI

Ingham RJ, Santos L, Dang-Lawson M, Holgado-Madruga M, Dudek P, Maroun CR, et al. The Gab1 docking protein links the b cell antigen receptor to the phosphatidylinositol 3-kinase/Akt signaling pathway and to the SHP2 tyrosine phosphatase. J Biol Chem (2001) 276:12257–65.  10.1074/jbc.M010590200 PubMed DOI

Mraz M, Chen L, Rassenti LZ, Ghia EM, Li H, Jepsen K, et al. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood (2014) 124:84–95.  10.1182/blood-2013-09-527234 PubMed DOI PMC

Saito K, Scharenberg AM, Kinet JP. Interaction between the Btk PH domain and phosphatidylinositol-3,4,5-trisphosphate directly regulates Btk. J Biol Chem (2001) 276:16201–6.  10.1074/jbc.M100873200 PubMed DOI

Park H, Wahl MI, Afar DE, Turck CW, Rawlings DJ, Tam C, et al. Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity (1996) 4:515–25. 10.1016/S1074-7613(00)80417-3 PubMed DOI

Rawlings DJ, Scharenberg AM, Park H, Wahl MI, Lin S, Kato RM, et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science (1996) 271:822–5. 10.1126/science.271.5250.822 PubMed DOI

Shinohara H, Yasuda T, Aiba Y, Sanjo H, Hamadate M, Watarai H, et al. PKC beta regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1. J Exp Med (2005) 202:1423–31.  10.1084/jem.20051591 PubMed DOI PMC

Shinohara H, Kurosaki T. Comprehending the complex connection between PKCbeta, TAK1, and IKK in BCR signaling. Immunol Rev (2009) 232:300–18.  10.1111/j.1600-065X.2009.00836.x PubMed DOI

Kang SW, Wahl MI, Chu J, Kitaura J, Kawakami Y, Kato RM, et al. PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization. EMBO J (2001) 20:5692–702.  10.1093/emboj/20.20.5692 PubMed DOI PMC

Chan VW, Meng F, Soriano P, DeFranco AL, Lowell CA. Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity (1997) 7:69–81. 10.1016/S1074-7613(00)80511-7 PubMed DOI

Pavlasova G, Mraz M. The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy. Haematologica (2020) 105:1494–506.  10.3324/haematol.2019.243543 PubMed DOI PMC

Pavlasova G, Borsky M, Svobodova V, Oppelt J, Cerna K, Novotna J, et al. Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels. Leukemia (2018) 32:2028–31.  10.1038/s41375-018-0211-0 PubMed DOI

Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, et al. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood (2016) 128:1609–13.  10.1182/blood-2016-04-709519 PubMed DOI PMC

Cerna K, Oppelt J, Chochola V, Musilova K, Seda V, Pavlasova G, et al. MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. Leukemia (2019) 33:403–14.  10.1038/s41375-018-0230-x PubMed DOI

Cerna K, Mraz M. p53 limits B cell receptor (BCR) signalling: a new role for miR-34a and FOXP1. Oncotarget (2018) 9:36409–10.  10.18632/oncotarget.26376 PubMed DOI PMC

Cui B, Chen L, Zhang S, Mraz M, Fecteau J-F, Yu J, et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood (2014) 124:546–54.  10.1182/blood-2014-03-559690 PubMed DOI PMC

Musilova K, Devan J, Cerna K, Seda V, Pavlasova G, Sharma S, et al. miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. Blood (2018) 132:2389–400.  10.1182/blood-2018-06-855502 PubMed DOI

Musilova K, Mraz M. MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia (2015) 29:1004–17.  10.1038/leu.2014.351 PubMed DOI

Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev (2009) 23:2839–49.  10.1101/gad.1861409 PubMed DOI PMC

Palacios F, Abreu C, Prieto D, Morande P, Ruiz S, Fernández-Calero T, et al. Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation. Leukemia (2015) 29:115–25.  10.1038/leu.2014.158 PubMed DOI

Psathas JN, Doonan PJ, Raman P, Freedman BD, Minn AJ, Thomas-Tikhonenko A. The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. Blood (2013) 122:4220–9.  10.1182/blood-2012-12-473090 PubMed DOI PMC

Carrasco YR. Batista FD. B-cell activation by membrane-bound antigens is facilitated by the interaction of VLA-4 with VCAM-1. EMBO J (2006) 25:889–99.  10.1038/sj.emboj.7600944 PubMed DOI PMC

Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T, et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood (2010) 115:4497–506.  10.1182/blood-2009-07-233692 PubMed DOI

Spaargaren M, Beuling EA, Rurup ML, Meijer HP, Klok MD, Middendorp S, et al. The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med (2003) 198:1539–50.  10.1084/jem.20011866 PubMed DOI PMC

Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, et al. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. J Exp Med (2018) 215:681–97.  10.1084/jem.20171288 PubMed DOI PMC

Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell’Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood (2000) 96:2655–63. 10.1182/blood.V96.8.2655.h8002655_2655_2663 PubMed DOI

Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood (1999) 94:3658–67. 10.1182/blood.V94.11.3658.423k11_3658_3667 PubMed DOI

Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood (2005) 106:1824–30.  10.1182/blood-2004-12-4918 PubMed DOI

Aguilar-Hernandez MM, Blunt MD, Dobson R, Yeomans A, Thirdborough S, Larrayoz M, et al. IL-4 enhances expression and function of surface IgM in CLL cells. Blood (2016) 127:3015–25.  10.1182/blood-2015-11-682906 PubMed DOI

Steele AJ, Prentice AG, Cwynarski K, Hoffbrand AV, Hart SM, Lowdell MW, et al. The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment. Blood (2010) 116:4569–77.  10.1182/blood-2009-09-245811 PubMed DOI

Ghia P, Strola G, Granziero L, Geuna M, Guida G, Sallusto F, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol (2002) 32:1403–13.  10.1002/1521-4141(200205)32:5&lt;1403::AID-IMMU1403<3.0.CO;2-Y PubMed DOI

Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The Lymph Node Microenvironment Promotes B-cell Receptor Signaling, NF-kappaB Activation, and Tumor Proliferation in Chronic Lymphocytic Leukemia. Blood (2011) 117:563–74.  10.1182/blood-2010-05-284984 PubMed DOI PMC

Ruan J, Hyjek E, Kermani P, Christos PJ, Hooper AT, Coleman M, et al. Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin’s lymphoma. Clin Cancer Res (2006) 12:5622–31.  10.1158/1078-0432.CCR-06-1204 PubMed DOI

Burger JA, Quiroga MP, Hartmann E, Bürkle A, Wierda WG, Keating MJ, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood (2009) 113:3050–8.  10.1182/blood-2008-07-170415 PubMed DOI PMC

Bürkle A, Niedermeier M, Schmitt-Gräff A, Wierda WG, Keating MJ, Burger JA. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood (2007) 110:3316–25.  10.1182/blood-2007-05-089409 PubMed DOI

Slinger E, Thijssen R, Kater AP, Eldering E. Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition. Leukemia (2017) 31:2601–7.  10.1038/leu.2017.129 PubMed DOI

Chang BY, Francesco M, De Rooij MFM, Magadala P, Steggerda SM, Huang MM, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood (2013) 122:2412–24.  10.1182/blood-2013-02-482125 PubMed DOI PMC

Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood (2014) 123:1810–7.  10.1182/blood-2013-09-527853 PubMed DOI PMC

Satterthwaite AB, Cheroutre H, Khan WN, Sideras P, Witte ON. Btk dosage determines sensitivity to B cell antigen receptor cross-linking. Proc Natl Acad Sci USA (1997) 94:13152–7.  10.1073/pnas.94.24.13152 PubMed DOI PMC

Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell (1993) 72:279–90. 10.1016/0092-8674(93)90667-F PubMed DOI

Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, et al. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight (2017) 2:e89904.  10.1172/jci.insight.89904 PubMed DOI PMC

Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia (2014) 28:649–57.  10.1038/leu.2013.358 PubMed DOI

Krysov S, Steele AJ, Coelho V, Linley A, Sanchez Hidalgo M, Carter M, et al. Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK. Blood (2014) 124:3101–9.  10.1182/blood-2014-04-567198 PubMed DOI PMC

Ponader S, Chen S-S, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (2012) 119:1182–9.  10.1182/blood-2011-10-386417 PubMed DOI PMC

Chen S-S, Chang BY, Chang S, Tong T, Ham S, Sherry B, et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia (2016) 30:833–43.  10.1038/leu.2015.316 PubMed DOI PMC

de Rooij MFM, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood (2012) 119:2590–4.  10.1182/blood-2011-11-390989 PubMed DOI

Ortolano S, Hwang I-Y, Han S-B, Kehrl JH. Roles for phosphoinositide 3-kinases, Bruton’s tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. Eur J Immunol (2006) 36:1285–95.  10.1002/eji.200535799 PubMed DOI

Rendeiro AF, Krausgruber T, Fortelny N, Zhao F, Penz T, Farlik M, et al. Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL. Nat Commun (2020) 11:577.  10.1038/s41467-019-14081-6 PubMed DOI PMC

Guinn D, Ruppert AS, Maddocks K, Jaglowski S, Gordon A, Lin TS, et al. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton’s tyrosine kinase inhibition with Ibrutinib. Leukemia (2015) 29:1210–3.  10.1038/leu.2014.344 PubMed DOI PMC

Saleh LM, Wang W, Herman SEM, Saba NS, Anastas V, Barber E, et al. Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia. Leukemia (2017) 31:340–9.  10.1038/leu.2016.181 PubMed DOI PMC

Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, et al. Ibrutinib Resistance in Chronic Lymphocytic Leukemia. New Engl J Med (2014) 370:2352–4.  10.1056/NEJMc1402716 PubMed DOI PMC

Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discovery (2014) 4:1022–35.  10.1158/2159-8290.CD-14-0098 PubMed DOI PMC

Epperla N, Shana’ah AY, Jones D, Christian BA, Ayyappan S, Maddocks K, et al. Resistance mechanism for ibrutinib in marginal zone lymphoma. Blood Adv (2019) 3:500–2.  10.1182/bloodadvances.2018029058 PubMed DOI PMC

Xu L, Tsakmaklis N, Yang G, Chen JG, Liu X, Demos M, et al. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. Blood (2017) 129:2519–25.  10.1182/blood-2017-01-761726 PubMed DOI PMC

Brandhuber B, Gomez E, Smith S, Eary T, Spencer S, Rothenberg SM, et al. LOXO-305, A Next Generation Reversible BTK Inhibitor, for Overcoming Acquired Resistance to Irreversible BTK Inhibitors. Clin Lymphoma Myeloma Leukemia (2018) 18:S216.  10.1016/j.clml.2018.07.081 DOI

Byrd JC, Smith S, Wagner-Johnston N, Sharman J, Chen AI, Advani R, et al. First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget (2018) 9:13023–35.  10.18632/oncotarget.24310 PubMed DOI PMC

Neuman LL, Ward R, Arnold D, Combs DL, Gruver D, Hill W, et al. First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects. Blood (2016) 128:2032–2.  10.1182/blood.V128.22.2032.2032 DOI

Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, et al. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discovery (2018) 8:1300–15.  10.1158/2159-8290.CD-17-1409 PubMed DOI PMC

Sun Y, Ding N, Song Y, Yang Z, Liu W, Zhu J, et al. Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas. Leukemia (2019) 33:2105–10.  10.1038/s41375-019-0440-x PubMed DOI

Sun Y, Zhao X, Ding N, Gao H, Wu Y, Yang Y, et al. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res (2018) 28:779–81.  10.1038/s41422-018-0055-1 PubMed DOI PMC

Liu T-M, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, et al. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood (2015) 126:61–8.  10.1182/blood-2015-02-626846 PubMed DOI PMC

Walliser C, Hermkes E, Schade A, Wiese S, Deinzer J, Zapatka M, et al. The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein. J Biol Chem (2016) 291:22136–48.  10.1074/jbc.M116.746842 PubMed DOI PMC

Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, et al. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer (2019) 125:559–74.  10.1002/cncr.31831 PubMed DOI

Wu C, de Miranda NF, Chen L, Wasik AM, Mansouri L, Jurczak W, et al. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations. Oncotarget (2016) 7:38180–90.  10.18632/oncotarget.9500 PubMed DOI PMC

Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med (2015) 21:922–6.  10.1038/nm.3884 PubMed DOI PMC

Xue L, Apatira M, Sirisawad M, Chang B. Abstract 1742: Ibrutinib plus proteasome or MALT1 inhibitors overcome resistance to BCR antagonists in CARD11 mutant-expressing B-lymphoma cells. In: Experimental and Molecular Therapeutics. Philadelphia, PA: American Association for Cancer Research; (2015). p. 1742–2.  10.1158/1538-7445.AM2015-1742 DOI

Lenz G, Balasubramanian S, Goldberg J, Rizo A, Schaffer M, Phelps C, et al. Sequence variants in patients with primary and acquired resistance to ibrutinib in the phase 3 MCL3001 (RAY) trial. J Clin Oncol (2016) 34:7570–0.  10.1200/JCO.2016.34.15_suppl.7570 DOI

Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, et al. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma. Nat Med (2014) 20:87–92.  10.1038/nm.3435 PubMed DOI

Mohanty A, Sandoval N, Das M, Pillai R, Chen L, Chen RW, et al. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget (2016) 7:73558–72.  10.18632/oncotarget.12434 PubMed DOI PMC

Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med (2019) 11(491):eaau1167.  10.1126/scitranslmed.aau1167 PubMed DOI

Agarwal R, Chan Y-C, Tam CS, Hunter T, Vassiliadis D, Teh CE, et al. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med (2019) 25:119–29.  10.1038/s41591-018-0243-z PubMed DOI

Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, et al. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. JCI Insight (2017) 2:1–14.  10.1172/jci.insight.90196 PubMed DOI PMC

Munshi M, Liu X, Chen JG, Xu L, Tsakmaklis N, Demos MG, et al. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer J (2020) 10:12.  10.1038/s41408-020-0277-6 PubMed DOI PMC

Choi J, Phelan JD, Wright GW, Häupl B, Huang DW, Shaffer AL, et al. Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14. Proc Natl Acad Sci USA (2020) 117:6092–102.  10.1073/pnas.1921187117 PubMed DOI PMC

Cosson A, Chapiro E, Bougacha N, Lambert J, Herbi L, Cung H-A, et al. Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1. Leukemia (2017) 31:1625–9.  10.1038/leu.2017.100 PubMed DOI

Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun (2016) 7:11589.  10.1038/ncomms11589 PubMed DOI PMC

Jiménez C, Chan GG, Xu L, Tsakmaklis N, Kofides A, Demos MG, et al. Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia. Br J Haematol (2020) 189(6):1165–70.  10.1111/bjh.16463 PubMed DOI PMC

Guerrera ML, Tsakmaklis N, Xu L, Yang G, Demos M, Kofides A, et al. MYD88 mutated and wild-type Waldenström’s Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4. Haematologica (2018) 103:e408–11.  10.3324/haematol.2018.190181 PubMed DOI PMC

Ahn IE, Underbayev C, Albitar A, Herman SEM, Tian X, Maric I, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood (2017) 129:1469–79.  10.1182/blood-2016-06-719294 PubMed DOI PMC

Quinquenel A, Fornecker L-M, Letestu R, Ysebaert L, Fleury C, Lazarian G, et al. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood (2019) 134:641–4.  10.1182/blood.2019000854 PubMed DOI

Scarfò L, Bonfiglio S, Sutton L-A, Ljungström V, Pandzic T, Cortese D, et al. BTK and PLCG2 Mutations In Patients With Chronic Lymphocytic Leukemia Relapsing On Ibrutinib: A European Research Initiative On CLL (ERIC) Study Based On Real-World Evidence. In: 25th Congress of the European Hematology Association (2020). Abstract S161. Available at: https://library.ehaweb.org/eha/2020/eha25th/294981/lydia.scarf.btk.and.plcg2.mutations.in.patients.with.chronic.lymphocytic.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D1766%2Amarker%3D756.

Gángó A, Alpár D, Galik B, Marosvári D, Kiss R, Fésüs V, et al. Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. Int J Cancer (2020) 146:85–93.  10.1002/ijc.32502 PubMed DOI

Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, et al. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol (2015) 1:80.  10.1001/jamaoncol.2014.218 PubMed DOI PMC

Sharma S, Galanina N, Guo A, Lee J, Kadri S, Van Slambrouck C, et al. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget (2016) 7:68833–41.  10.18632/oncotarget.11932 PubMed DOI PMC

Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, et al. BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol (2017) 35:1437–43.  10.1200/JCO.2016.70.2282 PubMed DOI PMC

Jones D, Woyach JA, Zhao W, Caruthers S, Tu H, Coleman J, et al. PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment. Leukemia (2017) 31:1645–7.  10.1038/leu.2017.110 PubMed DOI

Guarini A, Peragine N, Messina M, Marinelli M, Ilari C, Cafforio L, et al. Unravelling the suboptimal response of TP53 -mutated chronic lymphocytic leukaemia to ibrutinib. Br J Haematol (2019) 184:392–6.  10.1111/bjh.15613 PubMed DOI

Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood (2015) 125:2497–506.  10.1182/blood-2014-10-606038 PubMed DOI PMC

Brown JR, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, Coutre SE, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia (2018) 32:83–91.  10.1038/leu.2017.175 PubMed DOI PMC

O’Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood (2018) 131:1910–9.  10.1182/blood-2017-10-810044 PubMed DOI PMC

Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng P-H, Keats JJ, Wang H, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 9:1364–70.  10.1038/ni.1678 PubMed DOI PMC

Zarnegar BJ, Wang Y, Mahoney DJ, Dempsey PW, Cheung HH, He J, et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol (2008) 9:1371–8.  10.1038/ni.1676 PubMed DOI PMC

Hunter ZR, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood (2014) 123:1637–46.  10.1182/blood-2013-09-525808 PubMed DOI

Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood (2013) 122:1222–32.  10.1182/blood-2012-12-475111 PubMed DOI

Cao Y, Hunter ZR, Liu X, Xu L, Yang G, Chen J, et al. The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia. Leukemia (2015) 29:169–76.  10.1038/leu.2014.187 PubMed DOI

Cao Y, Hunter ZR, Liu X, Xu L, Yang G, Chen J, et al. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells. Br J Haematol (2015) 168:701–7.  10.1111/bjh.13200 PubMed DOI

Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J Clin Oncol (2019) 37:1285–95.  10.1200/JCO.18.02403 PubMed DOI PMC

Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature (2018) 560:387–91.  10.1038/s41586-018-0290-0 PubMed DOI PMC

Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell (2013) 155:1309–22.  10.1016/j.cell.2013.11.012 PubMed DOI PMC

Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell (2015) 27:240–56.  10.1016/j.ccell.2014.11.018 PubMed DOI PMC

Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell (2012) 21:227–39.  10.1016/j.ccr.2011.12.024 PubMed DOI PMC

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 468:973–7.  10.1038/nature09626 PubMed DOI PMC

Wilson FH, Johannessen CM, Piccioni F, Tamayo P, Kim JW, Van Allen EM, et al. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell (2015) 27:397–408.  10.1016/j.ccell.2015.02.005 PubMed DOI PMC

Kapoor I, Li Y, Sharma A, Zhu H, Bodo J, Xu W, et al. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. Cell Death Dis (2019) 10:924.  10.1038/s41419-019-2158-0 PubMed DOI PMC

Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, et al. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clin Cancer Res (2017) 23:4212–23.  10.1158/1078-0432.CCR-16-2703 PubMed DOI PMC

Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun (2017) 8:14920. 10.1038/ncomms14920 PubMed DOI PMC

Guan J, Huang D, Yakimchuk K, Okret S. p110α Inhibition Overcomes Stromal Cell–Mediated Ibrutinib Resistance in Mantle Cell Lymphoma. Mol Cancer Ther (2018) 17:1090–100.  10.1158/1535-7163.MCT-17-0784 PubMed DOI

Lukas M, Velten B, Sellner L, Tomska K, Hüellein J, Walther T, et al. Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies. Leukemia (2020).  10.1038/s41375-020-0846-5 PubMed DOI PMC

de Rooij MFM, Kuil A, Kater AP, Kersten MJ, Pals ST, Spaargaren M. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood (2015) 125:2306–9.  10.1182/blood-2014-12-619163 PubMed DOI PMC

Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. Lancet Haematol (2019) 6:e38–47.  10.1016/S2352-3026(18)30196-0 PubMed DOI PMC

Schmidl C, Vladimer GI, Rendeiro AF, Schnabl S, Krausgruber T, Taubert C, et al. Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL. Nat Chem Biol (2019) 15:232–40.  10.1038/s41589-018-0205-2 PubMed DOI PMC

Schaffer M, Chaturvedi S, Davis C, Aquino R, Stepanchick E, Versele M, et al. Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen. Leuk Lymphoma (2018) 59:931–40.  10.1080/10428194.2017.1349899 PubMed DOI

Hing ZA, Fung HYJ, Ranganathan P, Mitchell S, El-Gamal D, Woyach JA, et al. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies. Leukemia (2016) 30:2364–72.  10.1038/leu.2016.136 PubMed DOI PMC

Hing ZA, Mantel R, Beckwith KA, Guinn D, Williams E, Smith LL, et al. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Blood (2015) 125:3128–32.  10.1182/blood-2015-01-621391 PubMed DOI PMC

Ming M, Wu W, Xie B, Sukhanova M, Wang W, Kadri S, et al. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB. Mol Cancer Ther (2018) 17:2564–74.  10.1158/1535-7163.MCT-17-0789-ATR PubMed DOI

Guo A, Lu P, Coffey G, Conley P, Pandey A, Wang YL. Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment. Oncotarget (2017) 8:12953–67.  10.18632/oncotarget.14588 PubMed DOI PMC

Lee J, Zhang LL, Wu W, Guo H, Li Y, Sukhanova M, et al. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv (2018) 2:2039–51.  10.1182/bloodadvances.2018016048 PubMed DOI PMC

Forestieri G, Terzi di Bergamo L, Loh JW, Spina V, Zucchetto A, Condoluci A, et al. Mechanisms Of Adaptation To Ibrutinib In High Risk Chronic Lymphocytic Leukemia. In: 25th Congress of the European Hematology Association (2020). Abstract S154. Available at: https://library.ehaweb.org/eha/2020/eha25th/294974/gabriela.forestieri.mechanisms.of.adaptation.to.ibrutinib.in.high.risk.chronic.html?f=listing%3D4%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Aspeaker%3D663813.

Gaudio E, Tarantelli C, Kwee I, Barassi C, Bernasconi E, Rinaldi A, et al. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. Ann Oncol (2016) 27:1123–8.  10.1093/annonc/mdw131 PubMed DOI

Hillmen P, Rawstron AC, Brock K, Muñoz-Vicente S, Yates FJ, Bishop R, et al. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. J Clin Oncol (2019) 37:2722–9.  10.1200/JCO.19.00894 PubMed DOI PMC

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med (2019) 380:2095–103.  10.1056/NEJMoa1900574 PubMed DOI PMC

Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, et al. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Clin Cancer Res (2015) 21:3705–15.  10.1158/1078-0432.CCR-14-2809 PubMed DOI PMC

Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, et al. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol (2019) 37:269–77.  10.1200/JCO.18.01580 PubMed DOI

Tahir SK, Smith ML, Hessler P, Rapp LR, Idler KB, Park CH, et al. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer (2017) 17:399.  10.1186/s12885-017-3383-5 PubMed DOI PMC

Kuo H-P, Ezell SA, Schweighofer KJ, Cheung LWK, Hsieh S, Apatira M, et al. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. Mol Cancer Ther (2017) 16:1246–56.  10.1158/1535-7163.MCT-16-0555 PubMed DOI

Wang YLL, Franzen C, Wang S, Venkataraman G, Li L, Niu N, et al. Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication. Blood (2019) 134:475–5.  10.1182/blood-2019-125396 DOI

Galicia-Vázquez G, Aloyz R. Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes. Front Oncol (2018) 8:411.  10.3389/fonc.2018.00411 PubMed DOI PMC

Mraz M, Zent CS, Church AK, Jelinek DF, Wu X, Pospisilova S, et al. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol (2011) 155:53–64.  10.1111/j.1365-2141.2011.08794.x PubMed DOI PMC

Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, et al. Targeting Wnt pathway in mantle cell lymphoma-initiating cells. J Hematol Oncol (2015) 8:63.  10.1186/s13045-015-0161-1 PubMed DOI PMC

Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, et al. BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. Blood (2018) 131:2047–59.  10.1182/blood-2017-10-811752 PubMed DOI

Rauert-Wunderlich H, Rudelius M, Berberich I, Rosenwald A. CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma. Cell Death Dis (2018) 9:86.  10.1038/s41419-017-0157-6 PubMed DOI PMC

Sun Z, Luo L. Abstract 1298: CD40L-CD40 signaling on B-cell lymphoma response to BTK inhibitors. In: Experimental and Molecular Therapeutics. New Orleans, LA: American Association for Cancer Research; (2016). p. 1298–8.  10.1158/1538-7445.AM2016-1298 DOI

Lam K-P, Kühn R, Rajewsky K. In Vivo Ablation of Surface Immunoglobulin on Mature B Cells by Inducible Gene Targeting Results in Rapid Cell Death. Cell (1997) 90:1073–83.  10.1016/S0092-8674(00)80373-6 PubMed DOI

Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell (2009) 139:573–86.  10.1016/j.cell.2009.08.041 PubMed DOI PMC

Kim JH, Kim WS, Ryu K, Kim SJ, Park C. CD79B limits response of diffuse large B cell lymphoma to ibrutinib. Leukemia Lymphoma (2016) 57:1413–22.  10.3109/10428194.2015.1113276 PubMed DOI

Ma J, Lu P, Guo A, Cheng S, Zong H, Martin P, et al. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. Br J Haematol (2014) 166:849–61.  10.1111/bjh.12974 PubMed DOI

Herman SEM, Mustafa RZ, Jones J, Wong DH, Farooqui M, Wiestner A. Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo. Clin Cancer Res (2015) 21:4642–51.  10.1158/1078-0432.CCR-15-0781 PubMed DOI PMC

Chen L, Ouyang J, Wienand K, Bojarczuk K, Hao Y, Chapuy B, et al. CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. Haematologica (2020) 105:1361–8.  10.3324/haematol.2019.216218 PubMed DOI PMC

Chiodin G, Dutton D, Martino EA, Drennan S, Tracy I, Ondrisova L, et al. High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients. Blood (2019) 134:1752–2.  10.1182/blood-2019-128899 DOI

Drennan S, Chiodin G, D’Avola A, Tracy I, Johnson PW, Trentin L, et al. Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients. Clin Cancer Res (2019) 25:2503–12.  10.1158/1078-0432.CCR-18-1286 PubMed DOI

Filip D, Mraz M. The role of MYC in the transformation and aggressiveness of “indolent” B-cell malignancies. Leuk Lymphoma (2020) 61:510–24.  10.1080/10428194.2019.1675877 PubMed DOI

Varano G, Raffel S, Sormani M, Zanardi F, Lonardi S, Zasada C, et al. The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition. Nature (2017) 546:302–6.  10.1038/nature22353 PubMed DOI

Boissard F, Fournié J-J, Quillet-Mary A, Ysebaert L, Poupot M. Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients. Blood Cancer J (2015) 5:e355–5.  10.1038/bcj.2015.74 PubMed DOI PMC

Jayappa KD, Portell CA, Gordon VL, Capaldo BJ, Bekiranov S, Axelrod MJ, et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv (2017) 1:933–46.  10.1182/bloodadvances.2016004176 PubMed DOI PMC

Chen S-S, Tam CS, Ramsay AG, Ravichandran P, Couto-Francisco NC, Ibrahim M, et al. CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton’s Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib. Blood (2019) 134:477–7.  10.1182/blood-2019-127255 DOI

Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, et al. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res (2010) 5:212–25.  10.1016/j.scr.2010.07.003 PubMed DOI PMC

Jung HJ, Chen Z, McCarty N. Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma. Leuk Lymphoma (2011) 52:1066–79.  10.3109/10428194.2011.562570 PubMed DOI

Lee C-G, Das B, Lin TL, Grimes C, Zhang X, Lavezzi T, et al. A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential. Br J Haematol (2012) 158:79–90.  10.1111/j.1365-2141.2012.09123.x PubMed DOI PMC

Medina DJ, Abass-Shereef J, Walton K, Goodell L, Aviv H, Strair RK, et al. Cobblestone-area forming cells derived from patients with mantle cell lymphoma are enriched for CD133+ tumor-initiating cells. PloS One (2014) 9:e91042.  10.1371/journal.pone.0091042 PubMed DOI PMC

O’Brien SM, Furman RR, Coutre SE, Flinn IW, Burger J, Blum K, et al. Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Blood (2016) 128:233–3.  10.1182/blood.V128.22.233.233 DOI

Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv (2019) 3:1553–62.  10.1182/bloodadvances.2018030007 PubMed DOI PMC

Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, et al. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. J Pharmacol Exp Ther (2017) 363:240–52.  10.1124/jpet.117.242909 PubMed DOI

Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet (2020) 395:1278–91.  10.1016/S0140-6736(20)30262-2 PubMed DOI PMC

Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood (2019) 134:851–9.  10.1182/blood.2019001160 PubMed DOI PMC

Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia (2019) 33:2762–6.  10.1038/s41375-019-0575-9 PubMed DOI

George B, Mullick Chowdhury S, Hart A, Sircar A, Singh SK, Nath UK, et al. Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas. Cancers (2020) 12:1328.  10.3390/cancers12051328 PubMed DOI PMC

Thijssen R, Ter Burg J, Garrick B, van Bochove GGW, Brown JR, Fernandes SM, et al. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood (2016) 128:574–83.  10.1182/blood-2016-02-700328 PubMed DOI

Delvecchio VS, Sana I, Mantione ME, Vilia MG, Ranghetti P, Rovida A, et al. Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis. Br J Haematol (2020) 189:475–88.  10.1111/bjh.16386 PubMed DOI

Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim K-H, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature (2011) 470:115–9.  10.1038/nature09671 PubMed DOI PMC

Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, et al. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood (2019) 134:111–22.  10.1182/blood.2018882555 PubMed DOI PMC

Goy A, Ramchandren R, Ghosh N, Munoz J, Morgan DS, Dang NH, et al. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL. Blood (2019) 134:1024–36.  10.1182/blood.2018891598 PubMed DOI PMC

Jerkeman M, Eskelund CW, Hutchings M, Räty R, Wader KF, Laurell A, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol (2018) 5:e109–16.  10.1016/S2352-3026(18)30018-8 PubMed DOI

Ujjani C, Wang H, Skarbnik A, Trivedi N, Ramzi P, Khan N, et al. A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL. Blood Adv (2018) 2:762–8.  10.1182/bloodadvances.2017015263 PubMed DOI PMC

Yang Y, Shaffer AL, Emre NCT, Ceribelli M, Zhang M, Wright G, et al. Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma. Cancer Cell (2012) 21:723–37.  10.1016/j.ccr.2012.05.024 PubMed DOI PMC

Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood (2019) 133:1011–9.  10.1182/blood-2018-10-879429 PubMed DOI PMC

Skarzynski M, Niemann CU, Lee YS, Martyr S, Maric I, Salem D, et al. Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy. Clin Cancer Res (2016) 22:86–95.  10.1158/1078-0432.CCR-15-1304 PubMed DOI PMC

Albertsson-Lindblad A, Freiburghaus C, Jerkeman M, Ek S. Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide. Exp Hematol Oncol (2019) 8:16.  10.1186/s40164-019-0141-1 PubMed DOI PMC

Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol (2019) 20:43–56.  10.1016/S1470-2045(18)30788-5 PubMed DOI

Buchner M, Brantner P, Stickel N, Prinz G, Burger M, Bär C, et al. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies. Br J Haematol (2010) 151:167–78.  10.1111/j.1365-2141.2010.08316.x PubMed DOI

Choi MY, Widhopf GF, Ghia EM, Kidwell RL, Hasan MK, Yu J, et al. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell (2018) 22:951–9.e3.  10.1016/j.stem.2018.05.018 PubMed DOI PMC

Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. New Engl J Med (2019) 380:2225–36.  10.1056/NEJMoa1815281 PubMed DOI

Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol (2017) 28:1050–6.  10.1093/annonc/mdx031 PubMed DOI

Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, et al. B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood (2017) 129:333–46.  10.1182/blood-2016-05-718775 PubMed DOI

El-Gamal D, Williams K, LaFollette TD, Cannon M, Blachly JS, Zhong Y, et al. PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. Blood (2014) 124:1481–91.  10.1182/blood-2014-05-574830 PubMed DOI PMC

Fontán L, Qiao Q, Hatcher JM, Casalena G, Us I, Teater M, et al. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. J Clin Invest (2018) 128:4397–412.  10.1172/JCI99436 PubMed DOI PMC

Saba NS, Wong DH, Tanios G, Iyer JR, Lobelle-Rich P, Dadashian EL, et al. MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia. Cancer Res (2017) 77:7038–48.  10.1158/0008-5472.CAN-17-2485 PubMed DOI PMC

Gobessi S, Laurenti L, Longo PG, Carsetti L, Berno V, Sica S, et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia (2009) 23:686–97.  10.1038/leu.2008.346 PubMed DOI

Zhuang J, Hawkins SF, Glenn MA, Lin K, Johnson GG, Carter A, et al. Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. Haematologica (2010) 95:110–8.  10.3324/haematol.2009.010272 PubMed DOI PMC

Ramadani F, Bolland DJ, Garcon F, Emery JL, Vanhaesebroeck B, Corcoran AE, et al. The PI3K Isoforms p110 and p110 Are Essential for Pre-B Cell Receptor Signaling and B Cell Development. Sci Signaling (2010) 3:ra60–0.  10.1126/scisignal.2001104 PubMed DOI PMC

Ali AY, Wu X, Eissa N, Hou S, Ghia J-E, Murooka TT, et al. Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration. Leukemia (2018) 32:1958–69.  10.1038/s41375-018-0012-5 PubMed DOI PMC

Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood (2011) 118:3603–12.  10.1182/blood-2011-05-352492 PubMed DOI PMC

Lannutti BJ, Meadows SA, Herman SEM, Kashishian A, Steiner B, Johnson AJ, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood (2011) 117:591–4.  10.1182/blood-2010-03-275305 PubMed DOI PMC

Lampson BL, Brown JR. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Invest Drugs (2017) 26:1267–79.  10.1080/13543784.2017.1384815 PubMed DOI PMC

Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol (2017) 18:297–311.  10.1016/S1470-2045(16)30671-4 PubMed DOI PMC

Liu N, Rowley BR, Bull CO, Schneider C, Haegebarth A, Schatz CA, et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Mol Cancer Ther (2013) 12:2319–30.  10.1158/1535-7163.MCT-12-0993-T PubMed DOI

de Frias M, Iglesias-Serret D, Cosialls AM, González-Gironès DM, Pérez-Perarnau A, Rubio-Patiño C, et al. Isoform-selective phosphoinositide 3-kinase inhibitors induce apoptosis in chronic lymphocytic leukaemia cells. Br J Haematol (2010) 150:108–11.  10.1111/j.1365-2141.2010.08151.x PubMed DOI

Krause G, Hassenrück F, Hallek M. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. DDDT (2018) 12:2577–90.  10.2147/DDDT.S142406 PubMed DOI PMC

Mensah F, Blaize J-P, Bryan L. Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date. OTT (2018) 11:4817–27.  10.2147/OTT.S142264 PubMed DOI PMC

Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med (2014) 370:997–1007.  10.1056/NEJMoa1315226 PubMed DOI PMC

Ghia P, Ljungström V, Tausch E, Agathangelidis A, Scheffold A, Scarfo L, et al. Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment. Blood (2016) 128:2770–0.  10.1182/blood.V128.22.2770.2770 DOI

Scheffold A, Jebaraj BMC, Tausch E, Bloehdorn J, Ghia P, Yahiaoui A, et al. IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia. Blood (2019) 134:534–47.  10.1182/blood.2018881029 PubMed DOI PMC

Murali I, Kasar S, McWilliams EM, Itchaki G, Tyekucheva S, Livitz D, et al. Activating MAPK Pathway Mutations Mediate Primary Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia (CLL). Blood (2018) 132:587–7.  10.1182/blood-2018-99-115304 PubMed DOI

Kim JH, Kim WS, Park C. Interleukin-6 mediates resistance to PI3K-pathway–targeted therapy in lymphoma. BMC Cancer (2019) 19:936.  10.1186/s12885-019-6057-7 PubMed DOI PMC

Harnessing p53 for targeted cancer therapy: new advances and future directions

FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia

In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing

FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia

miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors

LncRNAs in adaptive immunity: role in physiological and pathological conditions